• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Functionalization of MOF-5 with mono-substituents: effects on drug delivery behavior
【24h】

Functionalization of MOF-5 with mono-substituents: effects on drug delivery behavior

机译：用单级取代基的MOF-5官能化：对药物递送行为的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Metal organic frameworks (MOFs) are widely used in drug carrier research due to their tunability. The properties of MOFs can be adjusted through incorporation of mono-substituents to obtain pharmaceutical carriers with excellent properties. In this study, different functional groups of –NH _(2) , –CH _(3) , –Br, –OH and –CH _(2) CH are connected to MOF-5 to analyse the effect of mono-substituent incorporation on drug delivery properties. The resulting MOFs have similar structures, except for Br–MOF. The pore size of this series of MOFs ranges from 1.04 nm to 1.10 nm. Using oridonin (ORI) as a model drug, introduction of the functional groups appears to have a significant effect on the drug delivery performance of the MOFs. The IRMOFs can be ranked according to drug-loading capacity: MOF-5 > HO–MOF-5 > H _(3) C–MOF-5 = Br–MOF-5 > H _(2) N–MOF-5 > CH _(2) CH–MOF-5. The ORI release from ORI @IRMOFs is explored at two different pH values: 7.4 and 5.5, and the ORI@IRMOFs are ranked according to the cumulative release percentage of ORI: ORI@MOF-5 > ORI@Br–MOF-5 > ORI@H _(3) C–MOF-5 > ORI@H _(2) N–MOF-5 > CH _(2) CH–MOF-5 > ORI@ HO–MOF-5. In particular, the release behaviour of ORI@MOFs is described through a new model. The different drug delivery performance of MOFs may be due to the complex interactions between MOFs and ORI. In addition, the introduction of single substituents does not change the biocompatibility of MOFs. MTT in vitro experiments prove that this series of MOFs has low cytotoxicity. This study shows that the incorporation of single substituents can effectively adjust the drug delivery behaviour of MOFs, which is conducive to realization of personalized drug delivery modes. The introduction of active groups can also facilitate post-synthesis modification to achieve coupling of targeting groups. MOFs incorporated with single substituents perform favorably in terms of use as biomedical drug delivery alternative carriers in effective drug payload and flexible drug release.
机译：金属有机框架（MOF）由于其可调性而广泛用于药物载体研究。可以通过掺入单级取代基来调节MOF的性质，以获得具有优异性能的药物载体。在该研究中，-NH _（2），-CH _（3），-BR，-OH和-CH _（2）CH的不同官能团连接到MOF-5以分析单取代基掺入的影响关于药物递送性能。除BR-MOF之外，所得MOF具有相似的结构。该系列MOF的孔径为1.04nm至1.10nm。使用Oridonin（ORI）作为模型药物，引入官能团的引入似乎对MOF的药物递送性能产生显着影响。 IRMOFS可以根据药物负载能力排序：MOF-5> HO-MOF-5> H _（3）C-MOF-5 = BR-MOF-5> H _（2）N-MOF-5> CH _（2）CH-MOF-5。来自ORI @Irmofs的ORI释放是以两种不同的pH值探索：7.4和5.5，并且根据累积释放百分比的ORI @ MOF-5> ORI @ BR-MOF-5> ORI @ IRMOFS排名@H _（3）C-MOF-5> ORI @ H _（2）N-MOF-5> CH _（2）CH-MOF-5> ORI @ HO-MOF-5。特别地，通过新模型描述了ORI @ MOF的释放行为。 MOF的不同药物递送性能可能是由于MOF和ori之间的复杂相互作用。此外，单一取代基的引入不会改变MOF的生物相容性。 MTT体外实验证明，这一系列MOF具有低细胞毒性。本研究表明，单一取代基的掺入可以有效地调节MOF的药物递送行为，这有利于实现个性化药物递送模式。引入活性组也可以促进合成后修饰，以实现靶向组的偶联。用单一取代基的MOF掺入，在使用中以有效的药物有效载荷和柔性药物释放的生物医药药物递送替代载体进行了有利的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号